

**4th European Conference on Infections in Leukaemia (ECIL-4): Guidelines for
Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenzavirus,
Metapneumovirus, Rhinovirus, and Coronavirus**

**Hans H. Hirsch^{1,2,*}, Rodrigo Martino³, Katherine N. Ward⁴, Michael Boeckh⁵, Hermann
Einsele⁶, Per Ljungman⁷**

¹Division Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel,
Switzerland

²Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel,
Switzerland

³Department of Hematology, Autonomous University of Barcelona, Hospital de la Santa Creu
i Sant Pau. Barcelona, Spain

⁴Division of Infection & Immunity, University College London, London, United Kingdom

⁵Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center,
Seattle, WA, USA

⁶Department of Internal Medicine II, Julius-Maximilians-University Würzburg, Germany

⁷Dept of Hematology, Karolinska University Hospital and Div. of Hematology, Dept. of
Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

*Correspondence on behalf of the ECIL CARV working group: Hans H Hirsch, MD MS,
Transplantation & Clinical Virology, Department Biomedicine – Building Petersplatz,
University of Basel, Petersplatz 10, CH-4003 Basel, Switzerland Email:
hans.hirsch@unibas.ch, Phone: +41 61 267 3262, Fax: +41 61 267 3283

Abstract

Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). Progression to lower respiratory tract infection (LRTI) with clinical and radiological signs of pneumonia and respiratory failure appears to depend on the intrinsic virulence of the specific CARV as well as factors specific to the patient, the underlying disease and its treatment. To better define the current state of knowledge of CARVs in leukemia and HSCT patients, and to improve CARV diagnosis and management, a working group of the 4th European Conference on Infections in Leukaemia (ECIL-4) 2011 reviewed the literature on CARVs, graded the available quality of evidence and made recommendations according to the IDSA grading system. Due to differences in screening, clinical presentation and therapy for influenza and adenovirus, ECIL-4 recommendations are summarized for CARVs other than influenza and adenovirus.

Introduction

Community-acquired respiratory virus (CARV) infections include a variety of RNA viruses such as human orthomyxo-, paramyxo-, picorna-, and coronaviruses, and DNA viruses such as adeno-, boca-, and polyomaviruses (1, 2). CARVs are detectable in the general population throughout the year, but some CARVs show a pronounced seasonality in temperate climates, which can exceed epidemic thresholds (1, 3). CARV respiratory tract infections (RTI) range from asymptomatic replication to significant disease that typically affects the very young and the very old populations, patients with chronic medical conditions and with inherited, acquired or drug-induced immune dysfunction (1, 4). In the past 2 decades, CARV RTIs have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT) (5-9). These patients are at increased risk for progression to lower RTI (LRTI) with clinical and radiological signs of pneumonia, respiratory failure, and fatal outcome. The risk of LRTI and fatal outcome appears to reflect the intrinsic virulence of specific CARVs as well as factors specific to the patient, the underlying disease and its treatment.

To better define the impact of CARVs in leukemia and HSCT patients, and to improve their diagnosis and management, a working group of the 4th European Conference on Infections in Leukaemia (ECIL-4) 2011 reviewed the literature on CARVs, graded the available evidence and made recommendations according to the IDSA grading system (**supplement Table 1**). Since several aspects regarding influenzavirus and adenovirus are substantially different including availability of vaccines and use of specific antivirals, and screening of high-risk patients for occurrence of gastrointestinal and disseminated disease, respectively, ECIL recommendations are summarized for CARVs other than influenza and adenovirus (10).

Methods

PubMed was searched using each of the following terms: respiratory virus, respiratory syncytial virus, metapneumovirus, parainfluenza, rhinovirus, enterovirus, picornavirus, coronavirus, polyomavirus, bocavirus; together with leukemia, or hematopoietic transplantation, or HSCT, or bone marrow transplantation, or cord blood. Published studies were identified and reviewed in August 2011. In June 2012, 5 additional papers and one paper in press were identified. The majority of publications are retrospective observational studies, while few prospective studies have been published dealing with this topic.

CARV Diagnostic Considerations

The diagnosis of CARV RTI is dependent on the specimen and the laboratory assay(s) available. Potential specimens for diagnostic testing include nasopharyngeal aspirates (NPA), nasopharyngeal wash (NPW), swabs (preferably flocked for nasal sampling), tracheal aspirates (TA) and bronchoalveolar lavage (BAL) (1, 11). Pooling bilateral nasopharyngeal with throat swabs is often preferred over NPA or NPW for URTI, and BAL is preferred over TA for the diagnosis of LRTIs. Laboratory tests include:

- Nucleic acid amplification testing (NAT) used as a generic term to describe molecular genetic tests such as PCR and others for the detection of viral DNA or RNA.
- Direct antigen detection (DAD) used as a generic term to describe direct detection of antigens in a specimen using specific antibodies in different assay formats (direct fluorescent antigen; enzyme-linked immunoassay, immune chromatography etc.).
- Virus isolation by cell culture (VIC) used as a generic term to describe cell culture for the isolation of infectious, replicating viruses. VIC is performed using conventional and/or shell vial cell culture techniques that can be combined with DAD for agent identification.

VIC has a higher clinical specificity for disease, but requires a dedicated virology laboratory, is less sensitive than NAT and has a comparatively long turn-around time (TAT) of 2 to 5

days. DAD has a good clinical specificity, and a short TAT of <4 hours, but has a lower sensitivity compared to VIC and NAT (12-20). NAT is often preferred because of a higher sensitivity, an acceptable TAT of <24 hours, in addition to the potential of quantifying viral loads, multiplexing with other infectious agents, detecting genetic variants and molecularly characterizing nosocomial outbreaks in specialized laboratories.

Definitions of CARV Infection and Disease

The detection of CARV in asymptomatic patients is increased when using sensitive NAT (16, 21, 22). As outlined elsewhere previously (23), it is therefore important to distinguish between patients with CARV infection and CARV infectious disease. To provide a case definition comparable to one proposed by the European Centre for Disease Prevention and Control (ECDC) for influenza virus, the working group agreed to its adaptation for other CARVs in leukemia and HSCT patients (**Table 1**).

- Upper respiratory tract infection (URTI) was defined as the detection of CARVs above and including the larynx; e.g. in samples from nose, pharynx, larynx, conjunctivae or sinuses.
- URTI disease (URTID) was defined as the detection of CARVs in upper respiratory tract fluid specimens together with symptoms and/or signs and other causes excluded.
- Lower respiratory tract infection (LRTI) was defined as the detection of CARVs below the larynx; e.g. in samples from trachea, bronchus, bronchoalveolar sites.
- LRTI disease (LRTID) was defined as pathological sputum production, hypoxia or pulmonary infiltrates together with identification of CARVs in respiratory secretions, preferentially in samples taken from the sites of involvement (**Table 1**).

Characteristics of specific CARVs

(Human) Respiratory Syncytial Virus (RSV)

RSV falls into two distinct antigenic subgroups, A and B. Infections occur year-round but peak during the cold season, with increases in URTID (e.g. sinusitis, rhinitis and laryngitis) in young children, and LRTID (e.g. bronchiolitis and pneumonia) in neonates (3, 24). RSV RTI of patients with HSCT and/or other hematological diseases follow the community activity and reflect an increased risk of community-acquired, household, and nosocomial transmission (15, 25-27). In the past, the standard diagnostic assays have been DAD and VIC, but these techniques have been replaced or complemented by NAT in many centers (14, 28). RSV infections occur in 0.3% - 2.2% of pediatric patients with acute myeloid leukemia (29) and in 1%-12% of adult patients with hematological malignancy and HSCT (8, 30-36). Infection in the first 100 days after myeloablative allogeneic HSCT has been associated with an increased risk of persistent air flow decline at 1 year post-transplant (37). Progression to LRTID is observed in 38% (mean, range 0% - 68%) of leukemia and HSCT patients, with an average mortality of 32% (range 0-70%), as reviewed elsewhere (14, 38). Risk factors for LRTID include infection during pre-engraftment, lymphopenia, older age, allogeneic HSCT and severe immunodeficiency due a range of contributing factors (**Table 2**). Although the risk of a poor clinical outcome progressively increases with overall falling absolute lymphocyte counts (9), varying thresholds of lymphopenia have been reported in clinical studies (0.3 to $0.1 \times 10^9/L$) (8, 31, 32, 39). Rapid diagnostics, infection control measures and deferral of chemotherapy and/or HSCT are important considerations (22). Corticosteroid treatment is a risk factor in leukemia patients (30), but the role of corticosteroids is controversial, since improving respiratory function has been seen despite increasing RSV loads and prolonged shedding (40, 41). Currently, there is only limited evidence for effective treatments due to the lack of potent antiviral drugs and sufficiently powered, randomized controlled clinical trial (RCTs) (42, 43). However, pooling of published studies suggest that treating URTID in HSCT

and leukemia at risk for LRTID and treating manifest LRTID with ribavirin and intravenous immunoglobulin (IVIG) improves outcome (14, 33, 38). It should be recognized that proper metaanalyses were not possible and the results should therefore be interpreted with caution.

Human Parainfluenzavirus (HPIV)

The HPIV species -1,-2,-3 and -4 cause mild URTID throughout the year, but type-specific seasonal increases of URTID and LRTID with laryngotracheitis, bronchiolitis and pneumonia are seen in 15% of infected children during autumn and spring (3, 44). Diagnosis of HPIV infection has been largely made using DAD or VIC covering HPIV-1, -2 and -3, but is increasingly replaced by NAT also identifying HPIV-4. In adult and pediatric leukemia and HSCT patients, symptomatic HPIV infections have been reported to range from 2% - 7%, of which at least one third are manifest as LRTID (9, 32, 45-49). Among the pediatric patients, 90 percent of HPIV were deemed to be community-acquired. Given an estimated incubation period of 2.6 days (95% CI 2.1-3.1) (50) and a high rate of 17.9% asymptomatic shedding (36), outpatient and nosocomial outbreaks are not infrequent, indicating the need for infection control strategies (18, 46-48, 51-56). In HSCT recipients with URTID and LRTID, HPIV-3 is the most commonly detected type in children as well as in leukemia and HSCT patients (80%-90%) followed by HPIV-1 and -2 (44, 45, 57, 58). Non-myeloablative conditioning has been associated with HPIV URTI after 30 days post-transplant (48). URTI has been associated with significant airflow decline in 40% of patients (37), which may progress to LRTID in 13-37% and a fatal outcome in 10-30% (45, 57). Risk factors for LRTID have been reported as being higher corticosteroid exposure, neutropenia, lymphopenia, infection early after allogeneic HSCT, a higher APACHE II score, and co-infections (32, 45, 47, 48, 57-60). Treatment options are limited by the lack of effective agents and RCTs, although some centers consider treating HPIV-URTID in patients with risk factors for LRTID and HPIV-LRTID, with ribavirin and/or IVIG (8, 18, 31, 36, 37, 48, 61-64). Bronchiolitis obliterans

syndrome and obstructive airflow decline and has been associated with HPIV infection with the first 3 months after allogeneic HSCT, which persisted at 1 year of follow-up (37, 65).

Human Metapneumovirus (HMPV)

HMPV is a paramyxovirus closely related to RSV causing increases in URTID and tracheobronchitis in 5%-20% of children and adults during winter. HMPV infection is commonly diagnosed by NAT, and rates range from 2.5%-9% during the first 2 years after allogeneic HSCT (32, 66-68). Asymptomatic and prolonged shedding has been reported in HSCT patients (36, 69, 70). HPMV-URTID in HSCT patients can present with flu-like symptoms (66, 67). In HSCT patients with pneumonia, HMPV is frequently co-detected with other pathogens, including bacteria, fungi and other CARVs, as well as cytomegalovirus, all which obscure the attributable morbidity (32, 66). Recipient CMV seropositivity was a risk factor in one study of HSCT patients (36). Single cases of severe disease and fatal outcome have been reported (71, 72). No general recommendation for treatment can currently be made, although some centers consider treating HMPV-LRTID with ribavirin and/or IVIG despite the lack of supporting studies (19, 26, 32, 66, 67)

Human Coronavirus (HCoV)

HCoVs circulate throughout the year with a slight predominance in winter, presumably causing 10% to 30% of the “common cold”. HCoV are divided into group 1-like (CoV-229E and -NL63) and group 2-like (CoV-OC43 and HKU1) agents that are molecularly distinct. Although VIC and DAD are available, most centers use NAT in multiplex formats, reporting rates of 5.7% among acutely symptomatic patients. The incubation period has been estimated as 3.2 days (95% CI 2.8-3.7) (50) followed by a median detectability of 2-3 weeks. URTID with rhinitis, pharyngitis and laryngitis is the most common manifestation. Cases of LRTID with bronchitis, bronchiolitis, and pneumonia have been reported in very young (age

<1 year) and/or in immunodeficient patients (73-75). In HSCT patients, HCoV has been detected in 6.7% - 15.4%, but asymptomatic shedding may be as high as 41% (21). In symptomatic HSCT patients, co-infections with other pathogens are frequent. LRTID and pneumonia with fatal outcome occurs rarely (76). General recommendations for treatment are limited in view of the largely benign course, the lack of effective antiviral agents and appropriate clinical studies (21, 75, 77, 78).

Human Rhinovirus (HRhV)

HRhVs belong to the *picornaviridae* family and are divided into 3 species called A, B, and C encompassing more than 100 serotypes. HRhVs circulate throughout the year being the most common cause of URTID (rhinorrhea, postnasal drip, cough) and occasionally (trachea-)bronchitis (1). The incubation period has been estimated as 1.9 days (95% CI 1.4-2.4) (50). Diagnosis largely depends on NAT, although DAD for rapid testing and VIC is performed in specialized laboratories. In allogeneic HSCT recipient, HRhVs have been identified as the most frequent CARVs, reaching a cumulative incidence as high as 22.3% by day 100 (21), with detection rates of up to 40% among symptomatic HSCT patients (34). HRhV infection may be asymptomatic in 13% of HSCT patients, and prolonged shedding over 4 weeks is frequent, with co-infections with other CARVs occurring in 19% (79). One study reports that higher HRhV loads correlate with symptomatic presentations (80). LRTID with frank pneumonia is rare and may occur in <10% of allogeneic HSCT infected with HRhV, usually in myeloablative conditioning, with an estimated mortality of less than 10% (32, 59, 79, 81). The role of HRhV treatment is limited by the lack of agents and clinical trials.

Other CARVs

Human enteroviruses (HEnV) encompassing at least 66 serotypes also belong to the *picornaviridae*. HEnVs are detected in <5% of hematological patients with URTID which may

progress to LRTID in 13% (9, 34, 79). Although some HEnV are identifiable by VIC, current laboratory diagnosis relies mostly on NAT, which may also be designed to detect other picornaviruses such as HRhV or parechoviruses. Lymphopenia of <500 / μ L is a risk factor for LRTID in HSCT patients.

Human bocavirus (HBoV), and human polyomavirus (HPyV) infections have been detected in patients with hematological malignancies or HSCT (82). However, studies of cases with a well-documented clinical course and proven disease by histopathology are missing. Accordingly, risk factors for disease and the need for therapy are not well defined. HBoV belongs to the *parvoviridae* family and is detected in 5% of children with RTI. HBoV has been frequently co-detected with other viral agents, preventing an unequivocal attribution to URTID or LRTID. In BAL from adult patients, HBoV was detected in 0% - 3% of cases. Recent studies suggest that HBoV loads above 5 \log_{10} copies/mL in respiratory fluids are more likely to indicate clinically significant replication (83). Disseminated HBoV infection has been reported, but the clinical interpretation of NAT signals, even when found in blood or organ sites may be difficult, since its prolonged persistence has been described akin to parvovirus B19 (84).

Human polyomavirus (HPyV)-RTI include KIPyV and WUPyV, which have been detected in 0.2% and 1.4% of children with acute URTID, respectively (85). KIPyV has been detected more frequently in respiratory fluids of HSCT patients (17%) compared to other patients (5%) (86). In symptomatic children with leukemia or HSCT, higher viral loads in BAL have been reported (87). In a large prospective study of 222 HSCT patients, KIPyV and WUPyV showed a cumulative incidence of 26% and 8% after 1 year, respectively, with no seasonal pattern, but an increased rate in patients <20 years of age (HR 4.4 and 4.6, respectively) (88). Sputum production and wheezing were associated with KIPyV or WUPyV detection, but not with GvHD, CMV reactivation, neutropenia, lymphopenia, hospitalization or death (88).

Pending further studies, routine testing for KIPyV and WUPyV cannot be recommended, and there are currently no data supporting the treatment of KIPyV- or WUPyV-LRTID (86).

ECIL-4 Recommendations on Prevention of CARV infection

The working group recognizes that the person-to-person transmission of CARVs should lead to measures for their prevention through infection control measures (**Table 3**). These recommendations should be implemented at the level of patients, relatives and healthcare workers (HCWs), both inside and outside of medical institutions (**Table 3**).

Administration of intravenous immunoglobulin (IVIG) preparations to HSCT and leukemia patients with hypogammaglobulinemia <4 g/L may reduce the risk of morbidity or mortality secondary to CARV-RTIDs (**CIII**). During RSV outbreaks in the community indicating an increased risk of exposure, the use of intravenous monoclonal antibody specific for the RSV-F protein (palivizumab) may be considered for pediatric patients age <2 years as monthly prophylaxis (**CIII**), but it is not indicated in other patient groups.

ECIL-4 Recommendations for Diagnosis of CARV infection

To balance costs and clinical benefit, screening all patients for CARVs is currently not indicated unless indicated in the context of an infection control investigation of nosocomial transmission and prevention, and thus laboratory testing should focus on symptomatic patients (**Table 4**). Taking into account the clinical impact of CARVs in HSCT and leukemia patients and the differences amongst centers in the technical and financial resources for comprehensive CARV diagnostics by multiplex NAT, the working group recommends prioritizing laboratory tests for specific CARVs such as Influenza, RSV, and HPIV (**Table 4**).

ECIL-4 Treatment Recommendations for CARV infection

Reflecting the clinical impact compared to other CARVs, the working group distinguishes the need of treatment for Influnza A and B (10), RSV and HPIV, taking into account the higher risk for poor outcome in specific patient groups. The treatment of RSV and HPIV may involve the deferral of conditioning therapy, the treatment with aerosolized ribavirin, the off-label use of systemic ribavirin, whereas no general recommendations for other CARVs can be made at this time (**Table 5**).

The corresponding modalities of RSV therapy and systemic ribavirin are summarized in **Table 6 and 7**, respectively. The working group is cautious about the use of intravenous monoclonal antibody specific for the RSV-F protein, since existing data outside of single case reports do not support its beneficial effect and the cost is very high. Therefore, only very young (< 2 y.o.) allogeneic HSCT patients with LRTID or at high risk for progression to RSV-LRTID might be considered for treatment with intravenous monoclonal antibody specific for the RSV-F protein e.g. palivizumab 15mg/ kg body weight (**CIII**), while this drug should not be considered in other patient groups.

Withholding treatment for RSV infection might be considered for selected stable leukemia and HSCT patients after careful evaluation of risk factors for morbidity and mortality and the possibility of appropriate follow-up visits considering e.g. remission of underlying disease, absence of immunosuppressive drug treatment, absence of the risk factors associated with LRTID or mortality (**CIII**). Although some centers would treat patients with HPIV-URTID and risk factors listed in Table 3, treatment of HPIV-URTID is not generally recommended given the clinically undefined risk and benefit ratio of treating HPIV-URTID (**CIII**).

Overall, the evidence is more limited for patients with autologous HSCT and/or hemato-oncological disease.

Infection control measures should be applied to patients undergoing autologous HSCT or chemotherapy for hemato-oncological diseases with CARV-URTID or -LRTID (**BIII**).

Deferral of conditioning/chemotherapy should be considered for patients with CARV-RTID scheduled for autologous HSCT or chemotherapy for hemato-oncological diseases (**BIII**).

Treatment of CARV-RTID other than influenza is not generally recommended for patients undergoing autologous HSCT or chemotherapy for hemato-oncological diseases (**CIII**).

Discussion and Outlook

The working group acknowledges that despite the growing awareness of infections by CARVs in HSCT and leukemia patients, well-designed studies are largely lacking that evaluate diagnostic and therapeutic strategies for CARV. On the diagnostic level, studies are needed to identify the most appropriate diagnostic test and specimen from the upper and lower respiratory tract. The detection of CARVs in peripheral blood has been associated with significant LRTID, disseminated disease and poor outcome, but requires evaluation by specifically designed studies. There is interest to identify and confirm risk factors of severe disease and poor outcome, and to evaluate laboratory markers of virus-specific immunity as surrogate markers of disease and recovery. The recent attempts to use RSV loads as a virological surrogate marker of antiviral treatment by siRNA and/or clinical outcome may have a pacemaker role for other CARVs (89). Importantly, the currently available treatments for CARV URTID and LRTID lack rigorous evaluation in appropriately sized, prospective randomized controlled trials. This is needed for comparing aerosolized ribavirin with systemic (oral) ribavirin; for evaluating the role of expensive IVIG preparations in combination with ribavirin; for determining the use of intravenous monoclonal antibody specific for the RSV-F protein (palivizumab, motavizumab) as post-exposure prophylaxis for high-risk patients as

well as therapy for RSV URTID and LRTID. The development of vaccines is seen as an important area of research. Finally, a better understanding of the indirect alloimmune pathology of CARVs on clinical outcome is important (65), but also depends on a better definition of the direct viral impact.

The authors have no reported conflicts of interest.

Table 1: Definitions of CARV Respiratory Tract Infectious Disease (RTID)

Case Classification

- **Possible case** - meeting the *clinical* criteria of RTID
- **Probable case** - meeting the *clinical* criteria of RTID together with an *epidemiological* link
- **Confirmed case** – meeting the *clinical* criteria of RTID and the *laboratory* criteria

Clinical criteria

- New onset of symptoms AND at least *one* of the following *four* respiratory symptoms:
 - Cough
 - Sore throat
 - Shortness of breath
 - Coryza
- AND The clinician's judgment that the illness is due to an infection

Epidemiological Criteria

- An epidemiological link to human-to-human transmission (activity in the community, contact with visitor, another patient, or health care worker)

Laboratory Criteria

- Detection of CARV in a clinical specimen, preferably from the site of clinical involvement, by at least one of the following:
 - Virus isolation by cell culture (VIC)
 - Direct virus antigen detection (DAD)
 - Nucleic acid amplification testing (NAT)
 - AND exclusion of a major role of other etiologies
-

Table 2: Risk factors of RSV-associated complications in HSCT patients

Progression to LRTID

- Lymphopenia $<0.2 \times 10^9/L$
- Older age
- Mismatched/unrelated donor
- Allogeneic HSCT <1 month
- Neutropenia $<500/\mu L$
- No therapy with aerosolized ribavirin + IVIG

Mortality

- Pre-engraftment
 - Lymphopenia $<0.2 \times 10^9/L$
 - Allogeneic HSCT <1 months
 - Severe immunodeficiency
 - Older age (>65 years)
-

HSCT, hematopoietic stem cell transplantation; LRTID, lower respiratory tract infectious disease;

Table 3: Recommendations on Prevention of CARV infection

-
- It is recommended that patients and contact persons should adhere to good personal hygiene, including frequent hand washing, covering the mouth when coughing and sneezing, and the safe disposal of oral and nasal secretions (**AII**).
 - Leukemia patients and HSCT patients should avoid contact with individuals with RTI in the hospital and in the community (**AII**).
 - Young children should be restricted from visiting patients and wards because of the higher risk of CARV exposure, prolonged shedding and ease of transmission (**BII**).
 - All visitors and HCW with RTI should be restricted from access to patients and wards (**AII**).
 - Inside care facilities, infection control measures should be applied to leukemia and HSCT patients with RTI, including isolation rooms and application of strict protection measures (gloves, gowning, masks, eye protection) for HCW and visitors (**AII**).
 - Outpatients with RTI should be seen and treated in accordance with infection control measures; i.e. in facilities and rooms separated from other HSCT and leukemia patients (**AII**).
-

CARV, community-acquired respiratory virus; HCW, health care worker; HSCT, hematopoietic stem cell transplantation; RTI, lower respiratory tract infection;

Table 4: Recommendations for Diagnosis of CARV infection

-
- HSCT candidates or HSCT recipients with URTID or LRTID should be tested for CARVs to guide infection control measures, treatment, and decisions regarding deferral of chemotherapy or HSCT (**AII**).
 - Specimens should preferably be taken from the site of clinical involvement, preferably pooled swabs for URTID, or BAL for LRTID, (or TA if BAL is not available) (**BII**).
 - First line diagnostic testing should be performed for Influenza-A and -B, RSV and HPIV (**AII**).
 - Testing for other CARVs (HMPV, HRhV, HCoV, HEnV, HAdV) should be considered according to risk of exposure, the local epidemiology, or if testing for the first line CARVs is negative (**BIII**).
 - Patients with LRTID should be considered for BAL and broader diagnostic testing including lung biopsy as clinically indicated (**BII**).
-

BAL, bronchoalveolar lavage; CARV, community-acquired respiratory virus; HPIV, human parainfluenza virus; HSCT, hematopoietic stem cell transplantation; LRTID, lower respiratory tract infectious disease; URTID, upper respiratory tract infectious disease; RSV, respiratory syncytial virus; TA, tracheal aspirate;

Table 5: Recommendation of CARV Treatment in HSCT and Leukemia Patients

-
- Deferral of conditioning therapy should be considered for patients with CARV-RTID planned for allogeneic HSCT. **(BII)**
 - Deferral of conditioning/chemotherapy could be considered for patients with CARV-RTID scheduled for chemotherapy of hemato-oncological diseases. **(BIII)**
 - Patients with RSV-URTID undergoing allogeneic HSCT, or recipients of allogeneic HSCT with risk factors for progression to RSV-LRTID and death should be treated with aerosolized or systemic ribavirin and IVIG. **(BII)**
 - For allogeneic HSCT patients with HPIV-LRTID, treatment with aerosolized or systemic ribavirin and IVIG may be considered. **(BIII)**
 - For allogeneic HSCT patients with CARV-URTID or CARV-LRTID other than RSV or HPIV, aerosolized or systemic ribavirin and IVIG treatment cannot be recommended. **(CIII)**
-

BAL, bronchoalveolar lavage; CARV, community-acquired respiratory virus; HPIV, human parainfluenza virus; HSCT, hematopoietic stem cell transplantation; IVIG, intravenous immunoglobulin; LRTID, lower respiratory tract infectious disease; URTID, upper respiratory tract infectious disease; RSV, respiratory syncytial virus;

Table 6: ECIL-4 Recommendation of RSV Treatment in hematological patients

-
- For treatment of RSV, aerosolized ribavirin can be administered as 2 g for 2 hours every 8 hours or as 6 g over 18 hours/day for 7-10 days (**BII**).
 - For treatments using aerosolized ribavirin, appropriate precautions should be applied to avoid environmental exposure and thereby potentially teratogenic effects in pregnant HCW and visitors (**AII**).
 - Patients on aerosolized ribavirin should be monitored and treated for adverse events including claustrophobia, bronchospasm, nausea, conjunctivitis and declining pulmonary function (**BII**).
 - For treatment of RSV, systemic ribavirin can be administered orally (**BIII**) or intravenously for patients unable to take oral medication (10mg – 30mg/kg body weight in three divided doses) (**CIII**).
 - Patients on systemic ribavirin should be monitored and treated for adverse events including hemolysis, abnormal liver function tests and declining renal function (**BIII**).
 - For allogeneic HSCT patients with RSV-LRTID or at high risk for RSV-LRTID, aerosolized or systemic ribavirin therapy may be combined with IVIG or anti-RSV-enriched antibody preparations (**BIII**).
-

CARV, community-acquired respiratory virus; HCW, health care worker; HSCT, hematopoietic stem cell transplantation; LRTID, lower respiratory tract infectious disease; URTID, upper respiratory tract infectious disease; RSV, respiratory syncytial virus;

Table 7: Use of systemic ribavirin for RSV- or HPIV-RTID*

Oral or intravenous ribavirin maximal dosing 10 mg/kg body weight every 8 hours for adults

Day 1: Start with 600 mg loading dose, then 200mg every 8h

Day 2: 400mg every 8h

Day 3: increase the dose to a maximum of 10mg/kg body weight every 8h

In case of adverse events: Decrease dose or discontinue ribavirin

Creatinine clearance: oral or intravenous administration

30-50 mL/min	maximal 200mg every 8h
--------------	------------------------

10-30 mL/ min	no recommendation can be given **
---------------	-----------------------------------

** some experts use 200mg once daily under close clinical and laboratory monitoring

* modified after (14)

HPIV, human parainfluenza virus; RSV, respiratory syncytial virus; RTID, upper respiratory tract infectious disease;

References

1. Turner RB. Upper Respiratory Tract Infections
Section B. In: Mandell DaBs, editor. Principles and Practice of Infectious Diseases. Seventh Edition ed. Philadelphia, Pennsylvania 19106: Elsevier Inc.; 2010. p. 809-13.
2. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. *Lancet*. 2011;377(9773):1264-75.
3. Hall CB. Respiratory syncytial virus and parainfluenza virus. *N Engl J Med*. 2001;344(25):1917-28.
4. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. *Am J Med*. 1997;102(3A):2-9; discussion 25-6.
5. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. *Am J Med*. 1997;102(3A):10-8; discussion 25-6.
6. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. *Br J Haematol*. 2008;143(4):455-67.
7. Ison MG. Respiratory syncytial virus and other respiratory viruses in the setting of bone marrow transplantation. *Curr Opin Oncol*. 2009;21(2):171-6.
8. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine (Baltimore)*. 2006;85(5):278-87.
9. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2001;28(5):479-84.

10.

http://www.ebmt.org/Contents/Resources/Library/ECIL/_layouts/mobile/view.aspx?List=9c1d8b11-2538-4794-a3d1-0320e97fe76c&View=f8038554-db71-45ae-ba17-5439cb906493).

11. Weigt SS, Gregson AL, Deng JC, Lynch JP, 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. *Semin Respir Crit Care Med*. 2011;32(4):471-93. Epub 2011/08/23.

12. Bredius RG, Templeton KE, Scheltinga SA, Claas EC, Kroes AC, Vossen JM. Prospective study of respiratory viral infections in pediatric hemopoietic stem cell transplantation patients. *Pediatr Infect Dis J*. 2004;23(6):518-22.

13. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. *Transpl Infect Dis*. 2009;11:298-303.

14. Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. *Clin Infect Dis*. 2008;46(3):402-12.

15. Kassis C, Champlin RE, Hachem RY, Hosing C, Tarrand JJ, Perego CA, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. *Biol Blood Marrow Transplant*. 2010;16(9):1265-71.

16. van Kraaij MG, van Elden LJ, van Loon AM, Hendriksen KA, Laterveer L, Dekker AW, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. *Clin Infect Dis*. 2005;40(5):662-9. Epub 2005/02/17.

17. van Elden LJ, van Kraaij MG, Nijhuis M, Hendriksen KA, Dekker AW, Rozenberg-Arska M, et al. Polymerase chain reaction is more sensitive than viral

culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. *Clin Infect Dis*. 2002;34(2):177-83.

18. Piralla A, Percivalle E, Di Cesare-Merlone A, Locatelli F, Gerna G. Multicenter nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. *Haematologica*. 2009;94(6):833-9.

19. Campbell AP, Chien JW, Kuypers J, Englund JA, Wald A, Guthrie KA, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. *J Infect Dis*. 2010;201(9):1404-13. Epub 2010/03/31.

20. Lee JH, Jang JH, Lee SH, Kim YJ, Yoo KH, Sung KW, et al. Respiratory viral infections during the first 28 days after transplantation in pediatric hematopoietic stem cell transplant recipients. *Clin Transplant*. 2012. Epub 2012/03/06.

21. Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, Corey L, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. *Blood*. 2010;115(10):2088-94.

22. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. *Clin Infect Dis*. 2004;39(5):673-80.

23. Relman DA, Falkow S. Microbial Pathogenesis
Section A. In: Mandell DaBs, editor. *Principles and Practice of Infectious Diseases*. Seventh Edition ed. Philadelphia, Pennsylvania 19106: Elsevier Inc.; 2010. p. 3-13.

24. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet*. 2010;375(9725):1545-55.

25. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on

engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant. 2003;32(2):195-203.

26. Machado AF, Sallum MA, Vilas Boas LS, Tateno AF, Machado CM. Molecular characterization of strains of respiratory syncytial virus identified in a hematopoietic stem cell transplant outpatient unit over 2 years: community or nosocomial infection? Biol Blood Marrow Transplant. 2008;14(12):1348-55.

27. Lavergne V, Ghannoum M, Weiss K, Roy J, Beliveau C. Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program. Bone Marrow Transplant. 2011;46(1):137-42.

28. Kuypers J, Wright N, Ferrenberg J, Huang ML, Cent A, Corey L, et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol. 2006;44(7):2382-8.

29. Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51(6):784-6.

30. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92(9):1216-23. Epub 2007/08/02.

31. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl:11S-5S.

32. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781-96.

33. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. *Transplantation*. 2009;88(10):1222-6.
34. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. *Bone Marrow Transplant*. 2003;32(1):73-7.
35. McCarthy AJ, Kingman HM, Kelly C, Taylor GS, Caul EO, Grier D, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. *Bone Marrow Transplant*. 1999;24(12):1315-22.
36. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. *Blood*. 2007;110(5):1681-8.
37. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. *J Infect Dis*. 2006;193(12):1619-25.
38. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. *Blood*. 2011;117(10):2755-63.
39. Khanna N, Hirsch HH. Respiratory Syncytial Virus Infection in Immunocompromised Patients Revisited. *Clinical Infectious Diseases*. 2008;46(12):1934-5.
40. Buckingham SC, Jafri HS, Bush AJ, Carubelli CM, Sheeran P, Hardy RD, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. *J Infect Dis*. 2002;185(9):1222-8.
41. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. *Transpl Infect Dis*. 2010;12(1):38-44.

42. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. *Ann Pharmacother*. 2012;46(4):558-66. Epub 2012/03/08.
43. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. *Clin Infect Dis*. 2007;44(2):245-9.
44. Laurichesse H, Dedman D, Watson JM, Zambon MC. Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997. *Eur J Epidemiol*. 1999;15(5):475-84.
45. Chemaly RF, Hanmod SS, Rathod DB, Ghantaji SS, Jiang Y, Doshi A, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. *Blood*. 2012;119(12):2738-45; quiz 969. Epub 2012/01/17.
46. Srinivasan A, Wang C, Yang J, Inaba H, Shenep JL, Leung WH, et al. Parainfluenza virus infections in children with hematologic malignancies. *Pediatr Infect Dis J*. 2011;30(10):855-9. Epub 2011/05/05.
47. Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT. Symptomatic Parainfluenza Virus Infections in Children Undergoing Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2011.
48. Ustun C, Slaby J, Shanley RM, Vydra J, Smith AR, Wagner JE, et al. Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time. *Biol Blood Marrow Transplant*. 2012. Epub 2012/04/26.
49. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. *Clin Infect Dis*. 1996;23(5):1033-7.

50. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis*. 2009;9(5):291-300.
51. McCann S, Byrne JL, Rovira M, Shaw P, Ribaud P, Sica S, et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. *Bone Marrow Transplant*. 2004;33(5):519-29.
52. Cortez KJ, Erdman DD, Peret TC, Gill VJ, Childs R, Barrett AJ, et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. *J Infect Dis*. 2001;184(9):1093-7.
53. Hohenthal U, Nikoskelainen J, Vainionpaa R, Peltonen R, Routamaa M, Itala M, et al. Parainfluenza virus type 3 infections in a hematology unit. *Bone Marrow Transplant*. 2001;27(3):295-300.
54. Sydnor ER, Greer A, Budd AP, Pehar M, Munshaw S, Neofytos D, et al. An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. *Am J Infect Control*. 2012. Epub 2012/03/13.
55. Maziarz RT, Sridharan P, Slater S, Meyers G, Post M, Erdman DD, et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant*. 2010;16(2):192-8.
56. Zambon M, Bull T, Sadler CJ, Goldman JM, Ward KN. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. *J Clin Microbiol*. 1998;36(8):2289-93. Epub 1998/07/17.
57. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. *Blood*. 2001;98(3):573-8.
58. Marcolini JA, Malik S, Suki D, Whimbey E, Bodey GP. Respiratory disease due to parainfluenza virus in adult leukemia patients. *Eur J Clin Microbiol Infect Dis*. 2003;22(2):79-84. Epub 2003/03/11.

59. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. *Haematologica*. 2009;94(8):1101-8.
60. Hodson A, Kasliwal M, Streetly M, Macmahon E, Raj K. A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. *Bone Marrow Transplant*. 2011.
61. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoietic stem cell transplant recipients: response to ribavirin therapy. *Clin Infect Dis*. 2000;31(6):1516-8.
62. Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. *Int J Hematol*. 2008;88(3):336-40.
63. Stankova J, Carret AS, Moore D, McCusker C, Mitchell D, Davis M, et al. Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. *Pediatr Transplant*. 2007;11(2):209-13.
64. Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J, Ringden O, Winiarski J, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. *Bone Marrow Transplant*. 1997;19(9):905-8.
65. Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB, Boelens JJ. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes. *Biol Blood Marrow Transplant*. 2010;16(6):782-91.
66. Debur MC, Vidal LR, Stroparo E, Nogueira MB, Almeida SM, Takahashi GA, et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. *Transpl Infect Dis*. 2010;12(2):173-9.

67. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. *J Infect Dis.* 2005;192(6):1061-5.
68. Oliveira R, Machado A, Tateno A, Boas LV, Pannuti C, Machado C. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. *Bone Marrow Transplant.* 2008;42(4):265-9.
69. Debiaggi M, Canducci F, Sampaolo M, Marinozzi MC, Parea M, Terulla C, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. *J Infect Dis.* 2006;194(4):474-8.
70. Debiaggi M, Canducci F, Terulla C, Sampaolo M, Marinozzi MC, Alessandrino PE, et al. Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. *New Microbiol.* 2007;30(3):255-8.
71. Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. *J Heart Lung Transplant.* 2007;26(8):862-4.
72. Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. *Ann Intern Med.* 2006;144(5):344-9.
73. Gerna G, Campanini G, Rovida F, Percivalle E, Sarasini A, Marchi A, et al. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. *J Med Virol.* 2006;78(7):938-49. Epub 2006/05/25.
74. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. *Chest.* 1999;115(3):901-5.

75. Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. *Clin Infect Dis*. 2003;37(7):929-32.
76. Uhlenhaut C, Cohen JL, Pavletic S, Illei G, Gea-Banacloche JC, Abu-Asab M, et al. Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia. *Transpl Infect Dis*. 2011.
77. Gerna G, Campanini G, Rognoni V, Marchi A, Rovida F, Piralla A, et al. Correlation of viral load as determined by real-time RT-PCR and clinical characteristics of respiratory syncytial virus lower respiratory tract infections in early infancy. *J Clin Virol*. 2008;41(1):45-8.
78. Oosterhof L, Christensen CB, Sengelov H. Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient. *Bone Marrow Transplant*. 2010;45(6):1115-6.
79. Parody R, Rabella N, Martino R, Otegui M, del Cuerdo M, Coll P, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. *Am J Hematol*. 2007;82(9):807-11.
80. Gerna G, Piralla A, Rovida F, Rognoni V, Marchi A, Locatelli F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. *J Med Virol*. 2009;81(8):1498-507.
81. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. *Bone Marrow Transplant*. 2007;40(8):809-11.
82. Schenk T, Strahm B, Kontny U, Hufnagel M, Neumann-Haefelin D, Falcone V. Disseminated bocavirus infection after stem cell transplant. *Emerg Infect Dis*. 2007;13(9):1425-7.

83. Gerna G, Piralla A, Campanini G, Marchi A, Stronati M, Rovida F. The human bocavirus role in acute respiratory tract infections of pediatric patients as defined by viral load quantification. *New Microbiol.* 2007;30(4):383-92. Epub 2007/12/18.
84. Schenk T, Maier B, Hufnagel M, Strahm B, Kontny U, Neumann-Haefelin D, et al. Persistence of human bocavirus DNA in immunocompromised children. *Pediatr Infect Dis J.* 2010;30(1):82-4.
85. Debiaggi M, Canducci F, Brerra R, Sampaolo M, Marinozzi MC, Parea M, et al. Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. *J Med Virol.* 2010;82(1):153-6.
86. Mourez T, Bergeron A, Ribaud P, Scieux C, de Latour RP, Tazi A, et al. Polyomaviruses KI and WU in immunocompromised patients with respiratory disease. *Emerg Infect Dis.* 2009;15(1):107-9.
87. Rao S, Garcea RL, Robinson CC, Simoes EA. WU and KI polyomavirus infections in pediatric hematology/oncology patients with acute respiratory tract illness. *J Clin Virol.* 2011;52(1):28-32. Epub 2011/06/28.
88. Kuypers J, Campbell AP, Guthrie KA, Wright NL, Englund JA, Corey L, et al. WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplantation Receipients. *CDC; Emerging Infectious Diseases*; 2012.
89. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. *Am J Respir Crit Care Med.* 2011;183(4):531-8.